Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference

Rhea-AI Summary

Neurocrine Biosciences, Inc. (NBIX) will present at the BofA Securities 2024 Health Care Conference, featuring top executives discussing the company's commitment to developing life-changing treatments for neurological disorders. The conference will be webcasted live and a replay will be available on the company's website. Neurocrine Biosciences has a strong portfolio of FDA-approved treatments and a robust pipeline in late-stage development.

Positive

• Neurocrine Biosciences showcasing at the BofA Securities 2024 Health Care Conference signifies transparency and commitment to investors and the healthcare industry.

• The live webcast and replay accessibility on the company's website demonstrate a strong investor relations strategy.

• Neurocrine Biosciences' diverse portfolio of FDA-approved treatments and a promising pipeline indicates potential growth and innovation in the field of neurological disorders.

Negative

• None.

SAN DIEGO, May 7, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the BofA Securities 2024 Health Care Conference at 11:20 a.m. Pacific Time (2:20 p.m. Eastern Time) on Tuesday May 14, 2024 in Las Vegas. Kevin Gorman, Chief Executive Officer, Matt Abernethy, Chief Financial Officer, and Kyle Gano, Chief Business Development and Strategy Officer, will present at the conference.

The live presentation will be webcast and may be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (Formerly Twitter) and Facebook. (*in collaboration with AbbVie)

NEUROCRINE BIOSCIENCES, NEUROCRINE, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. The Neurocrine logo is a trademark of Neurocrine Biosciences, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-bofa-securities-2024-health-care-conference-302138797.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When and where will Neurocrine Biosciences present at the BofA Securities 2024 Health Care Conference?

Neurocrine Biosciences will present at the BofA Securities 2024 Health Care Conference at 11:20 a.m. Pacific Time on Tuesday, May 14, 2024, in Las Vegas.

Who will be presenting at the conference on behalf of Neurocrine Biosciences?

Kevin Gorman, Chief Executive Officer, Matt Abernethy, Chief Financial Officer, and Kyle Gano, Chief Business Development and Strategy Officer, will be presenting at the conference.

Where can the live presentation be accessed?

The live presentation will be webcasted and may be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com.

Will there be a replay of the webcast available?

Yes, a replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

What is the core focus of Neurocrine Biosciences' portfolio?

Neurocrine Biosciences' portfolio includes FDA-approved treatments for neurological disorders like tardive dyskinesia, chorea associated with Huntington's disease, endometriosis, and uterine fibroids, with a robust pipeline in mid- to late-phase clinical development.